Real-World Economic Impact of OnabotulinumtoxinA in Patients with Chronic Migraine

被引：0
|
作者：
Rothrock, John [1 ]
Bloudek, Lisa [2 ]
Houle, Timothy [3 ]
Andress-Rothrock, Diane [4 ]
Hanlon, Christopher [1 ]
Varon, Sepideh [2 ]
机构：
[1] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[2] Allergan, Irvine, CA USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[4] Univ Alabama Birmingham, Headache Treatment & Res Program, Birmingham, AL USA
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P03233
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review
    Salim, Amira
    Hennessy, Elise
    Sonneborn, Claire
    Hogue, Olivia
    Biswas, Sudipa
    Mays, Maryann
    Suneja, Aarushi
    Ahmed, Zubair
    Mata, Ignacio F.
    CNS DRUGS, 2024, 38 (06) : 481 - 491
  • [42] Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data
    Lanteri-Minet, Michel
    Ducros, Anne
    Francois, Clement
    Olewinska, Elzbieta
    Nikodem, Mateusz
    Dupont-Benjamin, Laure
    CEPHALALGIA, 2022, 42 (14) : 1543 - 1564
  • [43] Interim analysis of the real-world utilization and safety of onabotulinumtoxina for the prophylactic treatment of chronic migraine in an observational study in the European Union
    Matharu, M.
    Pascual, J.
    Remahl, I. Nilsson
    Straube, A.
    Johannes, C.
    Odom, D.
    Gutierrez, L.
    Andrews, E.
    Lum, A.
    CEPHALALGIA, 2015, 35 : 39 - 39
  • [44] Real-world Adherence to Subsequent CGRP mAb Treatment Among Chronic Migraine (CM) Patients Initially Treated with OnabotulinumtoxinA: A Retrospective Claims Analysis
    Dong, Yanan
    Gusovsky, Amanda
    Shah, Darshini
    Park, Tae Jin
    Zhao, Changgeng
    NEUROLOGY, 2023, 100 (17)
  • [45] Real-world evidence of the effectiveness and satisfaction with eptinezumab treatment in patients with chronic migraine
    Argoff, C.
    Khan, F.
    Herzog, S.
    Smith, R.
    Kotak, S.
    Sopina, L.
    Soni-Brahmbhatt, S.
    Kymes, S.
    HEADACHE, 2023, 63 : 160 - 161
  • [46] Real-world patient perspective on the burden and impact of migraine
    de la Torre, Elena Ruiz
    Martelletti, Paolo
    Craven, Audrey
    Walsh, Donna
    Evans, Simon
    Dumas, Paula
    Diener, Hans-Christoph
    Lanteri-Minet, Michel
    Schwedt, Todd J.
    Malkowski, Jean-Pierre
    Sodha, Monisha
    Walda, Susann
    Aronsson, Anne
    Laflamme, Annik
    Vo, Pamela
    CEPHALALGIA, 2017, 37 : 370 - 371
  • [47] Real-world patient perspective on the burden and impact of migraine
    de la Torre, Elena Ruiz
    Martelletti, Paolo
    Craven, Audrey
    Walsh, Donna
    Evans, Simon
    Dumas, Paula
    Diener, Hans-Christoph
    Lanteri-Minet, Michel
    Schwedt, Todd J.
    Malkowski, Jean-Pierre
    Sodha, Monisha
    Walda, Susann
    Aronsson, Anne
    Laflamme, Annik
    Vo, Pamela
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [48] Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
    Cohen, Joshua M.
    Thompson, Stephen
    Patterson-Lomba, Oscar
    Driessen, Maurice
    Seminerio, Michael
    Carr, Karen
    Mu, Fan
    NEUROLOGY, 2021, 96 (15)
  • [49] Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study
    Ahmed, Fayyaz
    Gaul, Charly
    Sommer, Katherine
    TOXICON, 2022, 214 : S3 - S4
  • [50] Real-world safety and efficacy of 155-195U OnabotulinumtoxinA in participants with chronic migraine: Results from the REPOSE study
    Ahmed, F.
    Gaul, C.
    Sommer, K.
    HEADACHE, 2021, 61 : 73 - 73
12345